Defining the benefits of desensitization therapy

Comment

Stanley C Jordan et al. Transplantation. 2013.

. 2013 Mar 27;95(6):e31-2.

doi: 10.1097/TP.0b013e3182845fe1.

No abstract available

Comment in

Reply to "Defining the benefits of desensitization therapy".
Singer AL, Alachkar N, Montgomery RA, Zachary AA. Singer AL, et al. Transplantation. 2013 Mar 27;95(6):e33. doi: 10.1097/TP.0b013e3182845ffb. Transplantation. 2013. PMID: 23507652 No abstract available.
Reply to "Defining the benefits of desensitization therapy".
Marfo K, Akalin E. Marfo K, et al. Transplantation. 2013 Mar 27;95(6):e33-4. doi: 10.1097/TP.0b013e3182846013. Transplantation. 2013. PMID: 23507653 No abstract available.

Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients.
Alachkar N, Lonze BE, Zachary AA, Holechek MJ, Schillinger K, Cameron AM, Desai NM, Dagher NN, Segev DL, Montgomery RA, Singer AL. Alachkar N, et al. Transplantation. 2012 Jul 27;94(2):165-71. doi: 10.1097/TP.0b013e318253f7b6. Transplantation. 2012. PMID: 22735712
Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients.
Marfo K, Ling M, Bao Y, Calder B, Ye B, Hayde N, Greenstein S, Chapochnick-Friedman J, Glicklich D, de Boccardo G, Kinkhabwala M, Akalin E. Marfo K, et al. Transplantation. 2012 Aug 27;94(4):345-51. doi: 10.1097/TP.0b013e3182590d2e. Transplantation. 2012. PMID: 22820699